Wockhardt is eyeing to launch its new antibiotic -- ZAYNICH in second half of FY25-26 within domestic market. The company has completed Global Phase III clinical study for this product. Also, the company has filed New Drug Application (NDA) with Drug Controller General of India (DCGI) for the same. Zaynich is a life-saving innovation for gram negative infections.
Further, the company is aiming $7 billion market opportunity in US and European market with this drug. The company has completed a pre-NDA (non-disclosure agreement) meeting with the US Food and Drug Administration (USFDA) in May 2025 and plans to file for approval with USFDA in second quarter of the current fiscal with potential launch in FY2026-27. Besides, the company plans to file for regulatory approval for Europe & Emerging markets in second half of FY26.
Wockhardt is a research based Global Pharmaceutical and Biotech company.
